Trial Profile
Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Ductal carcinoma; Early breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms HERBIN
- 27 Mar 2018 Status changed from recruiting to completed.
- 01 May 2013 New trial record